Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
NICE guidance (NG28) recommends that patients starting GLP-1 receptor agonists like Ozempic should have: Baseline assessment including HbA1c, renal function, and body weight Regular monitoring of glycaemic control and tolerability Review at 6 months to assess treatment response (defined as HbA1c reduction of at least 11 mmol/mol and weight loss of at least 3% of initial body weight) Ongoing assessment of cardiovascular risk factors Patients with pre-existing conditions require particular consideration
Natural GLP-1 survives only minutes in the bloodstream
Duty to Warn Despite this knowledge, plaintiffs allege: Warnings about gastroparesis were inadequate The permanence of stomach paralysis was understated Patients were not informed it could be irreversible Marketing emphasized weight loss benefits without balancing risks 3
Heart - cardiovascular protection Semaglutide protects the heart and blood vessels in ways that go beyond weight loss alone
Patients should understand the challenges around staying on medication, and that it is common for patients to stop
Stay Hydrated Water is essential for overall health and weight management
